The journey of remdesivir: from Ebola to COVID-19.
COVID-19
SARS-CoV-2
pandemic
remdesivir
Journal
Drugs in context
ISSN: 1745-1981
Titre abrégé: Drugs Context
Pays: England
ID NLM: 101262187
Informations de publication
Date de publication:
2020
2020
Historique:
received:
23
04
2020
revised:
01
05
2020
accepted:
04
05
2020
entrez:
18
6
2020
pubmed:
18
6
2020
medline:
18
6
2020
Statut:
epublish
Résumé
Countries around the world are currently fighting the coronavirus disease 2019 (COVID-19) pandemic, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a betacoronavirus, belonging to the same genus as severe acute respiratory syndrome (SARS)-CoV and Middle East respiratory syndrome (MERS)-CoV. Currently, there are no proven antiviral therapies for COVID-19. Numerous clinical trials have been initiated to identify an effective treatment. One leading candidate is remdesivir (GS-5734), a broad-spectrum antiviral that was initially developed for the treatment of Ebola virus (EBOV). Although remdesivir performed well in preclinical studies, it did not meet efficacy endpoints in a randomized trial conducted during an Ebola outbreak. Remdesivir holds promise for treating COVID-19 based on
Identifiants
pubmed: 32547625
doi: 10.7573/dic.2020-4-14
pii: dic-2020-4-14
pmc: PMC7250494
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Informations de copyright
Copyright © 2020 Pardo J, Shukla AM, Chamarthi G, Gupte A.
Déclaration de conflit d'intérêts
Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest. The International Committee of Medical Journal Editors (ICMJE) Potential Conflicts of Interests form for the authors is available for download at: https://www.drugsincontext.com/wp-content/uploads/2020/05/dic.2020-4-14-COI.pdf
Références
N Engl J Med. 2015 Apr 9;372(15):1381-4
pubmed: 25853741
Infez Med. 2020 Ahead of print Jun 1;28(2):174-184
pubmed: 32275259
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
Antiviral Res. 2019 Sep;169:104541
pubmed: 31233808
J Med Chem. 2017 Mar 9;60(5):1648-1661
pubmed: 28124907
N Engl J Med. 2020 Apr 30;382(18):1677-1679
pubmed: 32109012
N Engl J Med. 2019 Dec 12;381(24):2293-2303
pubmed: 31774950
Sci Transl Med. 2019 May 29;11(494):
pubmed: 31142680
Nat Med. 2020 Apr 23;:
pubmed: 32327757
JAMA. 2020 Jan 23;:
pubmed: 31971553
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Lancet. 2016 Jul 30;388(10043):498-503
pubmed: 27209148
N Engl J Med. 2014 Oct 9;371(15):1375-8
pubmed: 24805988
Sci Transl Med. 2017 Jun 28;9(396):
pubmed: 28659436
Pharmacotherapy. 2020 Jun;40(6):592-598
pubmed: 32281114
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Sci Rep. 2017 Mar 06;7:43395
pubmed: 28262699
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
Viruses. 2019 Apr 04;11(4):
pubmed: 30987343
JAMA. 2020 Apr 16;:
pubmed: 32297900
Clin Infect Dis. 2012 Apr;54(7):913-21
pubmed: 22267716
mBio. 2018 Mar 6;9(2):
pubmed: 29511076
Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776
pubmed: 32054787
J Infect Dis. 2017 Jan 15;215(2):171-174
pubmed: 28073857
Am J Transplant. 2020 Apr 24;:
pubmed: 32330343
ASAIO J. 2020 Apr 17;:
pubmed: 32317557
Life Sci. 2020 Jul 15;253:117592
pubmed: 32222463
Nature. 2016 Mar 17;531(7594):381-5
pubmed: 26934220
Nat Commun. 2020 Jan 10;11(1):222
pubmed: 31924756
Exp Biol Med (Maywood). 2009 Oct;234(10):1117-27
pubmed: 19546349
One Health. 2020 Mar 27;9:100128
pubmed: 32258351
Int J Antimicrob Agents. 2020 Apr;55(4):105933
pubmed: 32147516
Emerg Infect Dis. 2014 Jun;20(6):1012-5
pubmed: 24857749
Clin Drug Investig. 2008;28(7):409-20
pubmed: 18544001